Tocilizumab as a first-line biologic treatment in rheumatoid arthritis patients – the impact of concomitant methotrexate treatment and Rheumatic Disease Comorbidity Index on the clinical response – results from the multicenter observational ACT-POL study

OBJECTIVES: According to the EULAR recommendations, remission or low disease activity (LDA) in rheumatoid arthritis should be achieved by a maximum of 6 months (M6) of treatment. Data on the use of tocilizumab (TCZ) as first-line biologic treatment in rheumatoid arthritis (RA) in routine clinical pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Stajszczyk, Marcin, Jeka, Sławomir, Juś, Anna, Pawlak-Buś, Katarzyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238310/
https://www.ncbi.nlm.nih.gov/pubmed/35782029
http://dx.doi.org/10.5114/reum.2022.115986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238310/
https://www.ncbi.nlm.nih.gov/pubmed/35782029
http://dx.doi.org/10.5114/reum.2022.115986

Ejemplares similares